Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Restrictive REMS Is Least Favored Path For Opioid Prescriber Education

Executive Summary

FDA advisory committee's preferred approaches – linking mandatory training to DEA registration or state medical board licensing – are outside agency's existing regulatory authority.


Related Content

Opioids: Senate Wants Mandatory Prescriber Training; Can FDA Make It Work?
FDA Expanding Opioid REMS To Immediate Release Formulations
Opioid Prescriber Training: US FDA Still Debating Mandate; CMS Policies Having Impact Now
RoxyBond Clears US FDA With Abuse-Deterrent Properties, But No REMS Yet
Opioids: FDA Eyes Better Prescriber Education, But Academics Urge Promotion Crackdown
REMS Standardization Could Help Opioid Education Efforts
Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says
FDA's Opioid REMS Review Puts Brakes On Mandatory Education Push
Opioid REMS Needs Legislation Mandating Physician Training For Full Implementation
FDA Opioid REMS Proposal Leaves Advisory Panel Wanting More - i.e. Mandatory Training


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts